Astria Therapeutics Inc Ordinary Shares ATXS 深 沪
等待开盘 09-30 09:30:00 美东时间
7.36
+0.060
+0.82%
华盛通- 最 高7.48
- 今 开7.34
- 成交量 37.61万股
- 最 低 7.1926
- 昨 收 7.30
- 总市值 4.15亿
- 52周最高 12.515
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 3.555
- 委 比 90.32%
- 总股本 5643.49万
- 历史最高 1017.60
- 量 比 1.21
- 振 幅 3.94%
- 历史最低 2.36
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AtlasClear Holdings Inc. Engages PCG Advisory to Enhance Investor Relations, Digital Communications and Market Visibility
AtlasClear Holdings has partnered with PCG Advisory to enhance its investor relations and strategic communications, aiming to increase visibility in capital markets and strengthen connections with investors. This collaboration reflects the company's commitment to effectively communicate its strategy and progress, supporting its growth as it builds a next-generation financial services platform. PCG Advisory will help AtlasClear expand its investor...
09-25 12:30
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Astria Therapeutics Releases Initial Phase 1a Trial Results For STAR-0310 With Drug Showing Best-In-Class Half-Life Of Up To 68 Days Supporting Twice-Yearly Dosing, Demonstrated Durable Cytokine Inhibition, And Was Well-Tolerated With No ADCC-Related Side Effects
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial
09-17 20:07
JMP Securities Maintains Market Outperform on Astria Therapeutics, Raises Price Target to $26
JMP Securities analyst Jonathan Wolleben maintains Astria Therapeutics (NASDAQ:ATXS) with a Market Outperform and raises the price target from $25 to $26.
08-13 22:18
Astria Therapeutics Q2 EPS $(0.57) Beats $(0.59) Estimate
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 2.9 percent. This is a 32.56 percent decrease over losses of $(0.43) per share from
08-13 04:37
Astria Therapeutics Enters Licensing Deal with Kaken
Astria Therapeutics ( ($ATXS) ) just unveiled an update. On August 6, 2025, Ast...
08-06 20:28
Astria Therapeutics Licenses D&C Rights In Japan To Kaken Pharma For Navenibart In Phase 3 Development For Preventative Treatment Of HAE; Astria To Receive $16M Upfront, With Potential For $16M In Commercialization Milestones
-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties ---- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan ---- Updated
08-06 20:17
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics received formal acceptance of its patent application for the DRP® companion diagnostic specific to stenoparib from IP Australia. The acceptance covers 40 claims, marking a key step in the company's global strategy to protect the commercialization of its proprietary DRP® platform alongside clinical development. The granted patent will be advertised on June 26, 2025, followed by a three-month opposition period. CEO Thomas Jens...
06-30 12:00
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Astria Therapeutics Reports Initial Results From Target Enrollment Group In Ongoing ALPHA-SOLAR Long-Term Open-Label Trial Evaluating Navenibart In HAE Patients
-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction ---- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction –-- Well-Tolerated with a Favorable Safety Profile ---- All Patients Remain on Navenibart
06-13 19:02
